
NASDAQHealthcareBiotechnology
Latest quote
$2.80
−$0.13 · -4.44%
Nordicus Partners Corporation functions as a publicly traded entity that acts as both a business accelerator and a holding company, specifically supporting Nordic life sciences firms operating within the United States. A central focus for the company involves advancing oral healthcare through the development of new medicines. In addition to its core operations, Nordicus offers an array of corporate finance and advisory services. These include aiding in business and market expansion, formulating strategic growth plans, identifying and acquiring talent, fostering key partnerships, facilitating capital raising efforts, and orchestrating company acquisitions or sales. The organization, which was established in 1993 and is headquartered in Beverly Hills, California, rebranded as Nordicus Partners Corporation in May 2023, having previously been known as EKIMAS Corporation.
Previous close
$2.80
−$0.13 · -4.44%
Regular session · ET · Market data may be delayed.
Nordicus Partners Corporation functions as a publicly traded entity that acts as both a business accelerator and a holding company, specifically supporting Nordic life sciences firms operating within the United States. A central focus for the company involves advancing oral healthcare through the development of new medicines. In addition to its core operations, Nordicus offers an array of corporate finance and advisory services. These include aiding in business and market expansion, formulating strategic growth plans, identifying and acquiring talent, fostering key partnerships, facilitating capital raising efforts, and orchestrating company acquisitions or sales. The organization, which was established in 1993 and is headquartered in Beverly Hills, California, rebranded as Nordicus Partners Corporation in May 2023, having previously been known as EKIMAS Corporation.
Day range
Current $2.80
52-week range
Current $2.80
Regular session · ET · Market data may be delayed.
Nordicus Partners Corporation functions as a publicly traded entity that acts as both a business accelerator and a holding company, specifically supporting Nordic life sciences firms operating within the United States. A central focus for the company involves advancing oral healthcare through the development of new medicines. In addition to its core operations, Nordicus offers an array of corporate finance and advisory services. These include aiding in business and market expansion, formulating strategic growth plans, identifying and acquiring talent, fostering key partnerships, facilitating capital raising efforts, and orchestrating company acquisitions or sales. The organization, which was established in 1993 and is headquartered in Beverly Hills, California, rebranded as Nordicus Partners Corporation in May 2023, having previously been known as EKIMAS Corporation.
Day range
Current $2.80
52-week range
Current $2.80
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | 5K USD | 2.5K USD | — | — |
| Cost of goods sold | 5.2K USD | — | — | — | — |
| Gross profit | −5.2K USD | — | — | — | — |
| Research and development | 1.61M USD | 1.33M USD | — | — | — |
| Selling, general, and administrative | 1.83M USD | 683.5K USD | 191.61K USD | 298.79M USD | 309.17K USD |
| Operating expenses | 4.37M USD | 2.92M USD | 310.09K USD | 8.48B USD | 309K USD |
| Interest expense | −642 USD | 200 USD | — | −382K USD | — |
| Depreciation and amortization | 5.2K USD | 5.17K USD | — | — | 236.56K USD |
| Operating income | −4.37M USD | −2.92M USD | −307.59K USD | −8.47B USD | −309K USD |
| Net income | −4M USD | −2.9M USD | −298.2K USD | −8.46B USD | −265K USD |
Company facts updated Nov 22, 2026.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.